SPRC SciSparc Ltd.
$0.85▼ -34.11%
Healthcare
Other
Volume 1.80M
Avg Volume (10D) 8.02M
Key Metrics & Fundamentals
Market Cap
$493,827
P/E Ratio
0.0
Div Yield
0.00%
52W Range
0.73 - 34.65
% vs 50 MA
-81.22%
% vs 200 MA
-85.22%
RSI-14
17.7
MACD Histogram
-0.1800
Beta (1Y vs SPY)
0.08
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
NewMediaWire · Oct 22, 2026 9:02 AM ET
SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
GlobeNewswire · Oct 22, 2026 8:55 AM ET
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
GlobeNewswire · Oct 19, 2026 8:35 AM ET
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
GlobeNewswire · Oct 15, 2026 7:06 AM ET
SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture
GlobeNewswire · Oct 7, 2026 8:22 AM ET
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
GlobeNewswire · Sep 23, 2026 8:35 AM ET
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
NewMediaWire · Sep 2, 2026 9:16 AM ET
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
GlobeNewswire · Sep 2, 2026 8:17 AM ET
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI210 Autism Clinical Trial
NewMediaWire · Aug 31, 2026 4:05 PM ET
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
GlobeNewswire · Aug 31, 2026 4:03 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.